Anti-interleukin-5/anti-interleukin-5 receptor α treatment improves self-reported work productivity in patients with severe eosinophilic asthma: a prospective cohort trial

被引：1

作者：

Brinkmann, Lina ^{[1
]}

Fuge, Jan ^{[1
,2
]}

Welte, Tobias ^{[1
,2
]}

Suhling, Hendrik ^{[1
,2
]}

Drick, Nora ^{[1
,2
]}

机构：

[1] Hannover Med Sch, Dept Resp Med & Infect Dis, Hannover, Germany

[2] German Ctr Lung Res DZL, Biomed Res Endstage & Obstruct Lung Dis Hannover B, Hannover, Germany

来源：

ERJ OPEN RESEARCH | 2024年 / 10卷 / 06期

关键词：

COST-EFFECTIVENESS; PERSISTENT ASTHMA; THERAPY; OMALIZUMAB; BURDEN; EXACERBATIONS; MEPOLIZUMAB; DISABILITY; ANTIBODY; ADULTS;

D O I：

10.1183/23120541.00374-2024

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background Severe asthma affects the working life of millions of people worldwide. Interleukin (IL)-5/ anti-interleukin-5 receptor alpha (IL-5R alpha) antibodies are highly effective in reducing symptoms in patients with severe eosinophilic asthma. We analysed effects of anti-IL-5/anti-IL-5R alpha treatment on self-reported productivity and absenteeism at work in patients with severe eosinophilic asthma. Methods In this prospective single-centre study, patients with severe eosinophilic asthma received a questionnaire assessing their actual occupational status and the influence asthma has on their work life, productivity and missed days at work prior to initiation of antibody treatment and after 6 and 12 months of therapy. Among others, the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) was used. Results Out of 54 patients with a median age of 60 years, 27 (50%) were employed. In addition to an increase in asthma control and lung function, self-reported productivity increased significantly with a decrease on the WPAI:SHP from 30% (interquartile range (IQR) 20-50%) to 10% (IQR 0-27.5%) under treatment (p=0.001). Furthermore, self-reported missed days at work were reduced from 2 days month-1 (IQR 1.75-6 days month-1) to 0 days month-1 (IQR 0-2 days month-1; p=0.067). At baseline 22 employed patients (81%) stated they were affected at work by their asthma. After 12 months of treatment, this number decreased to eight patients (30%; p=0.038). Conclusions This prospective analysis could prove the substantial impact severe asthma has on patients' working life. Anti-IL-5/anti-IL-5R alpha treatment in patients with severe eosinophilic asthma leads to a significant increase in self-reported productivity at work, and after 12 months of treatment patients state substantially fewer negative effects on their working situation.

引用

页数：10

共 46 条

[1]

Global Strategy for Asthma Management and Prevention, (2023)

[2]

Hyland ME, Whalley B, Jones RC, Et al., A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales, Qual Life Res, 24, pp. 631-639, (2015)

[3]

Gruffydd-Jones K, Thomas M, Roman-Rodriguez M, Et al., Asthma impacts on workplace productivity in employed patients who are symptomatic despite background therapy: a multinational survey, J Asthma Allergy, 12, pp. 183-194, (2019)

[4]

Ding B, Chen S, Srivastava D, Et al., Symptom burden, health status, and productivity in patients with uncontrolled and controlled severe asthma in NOVELTY, J Asthma Allergy, 16, pp. 611-624, (2023)

[5]

Burnette A, Wang Y, Rane PB, Et al., Incremental cost burden among patients with severe uncontrolled asthma in the United States, J Manag Care Spec Pharm, 29, pp. 825-834, (2023)

[6]

Pavord ID, Korn S, Howarth P, Et al., Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial, Lancet, 380, pp. 651-659, (2012)

[7]

Bjermer L, Lemiere C, Maspero J, Et al., Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels, Chest, 150, pp. 789-798, (2016)

[8]

Nair P, Wenzel S, Rabe KF, Et al., Oral glucocorticoid–sparing effect of benralizumab in severe asthma, N Engl J Med, 376, pp. 2448-2458, (2017)

[9]

Wenzel S, Ford L, Pearlman D, Et al., Dupilumab in persistent asthma with elevated eosinophil levels, N Engl J Med, 368, pp. 2455-2466, (2013)

[10]

Busse W, Corren J, Lanier BQ, Et al., Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma, J Allergy Clin Immunol, 108, pp. 184-190, (2001)

← 1 2 3 4 5 →